Quick-Med Technologies, Inc. (QMDT)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Quick-Med Technologies, Inc. (QMDT) with AI Score 57/100 (Hold). Quick-Med Technologies, Inc. is a life sciences company focused on developing and commercializing proprietary technologies in the medical and consumer healthcare markets. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Quick-Med Technologies, Inc. (QMDT) Healthcare & Pipeline Overview
Quick-Med Technologies, Inc. operates in the specialty drug manufacturing sector, focusing on antimicrobial and hemostatic technologies. The company's NIMBUS, Stay Fresh, and MultiStat platforms target diverse applications in healthcare, textiles, and personal care, serving both government and commercial clients with specialized biomedical solutions.
Investment Thesis
Quick-Med Technologies, Inc. presents a speculative investment opportunity within the specialty drug manufacturing sector. The company's proprietary NIMBUS, Stay Fresh, and MultiStat technologies offer potential for growth in diverse markets, including healthcare, textiles, and personal care. With a negative P/E ratio of -0.02 and a negative profit margin of -76.8%, the company's financial performance indicates it is not currently profitable. A gross margin of 69.8% suggests strong potential profitability if sales volume increases. Key catalysts include successful commercialization of their technologies and partnerships with larger industry players. However, the company's small size (5 employees) and OTC market listing introduce significant risks related to liquidity and operational scalability. The beta of -39.80 suggests an inverse correlation with the market, but this may be unreliable due to the company's limited trading volume.
Based on FMP financials and quantitative analysis
Key Highlights
- Gross Margin of 69.8% indicates strong potential profitability if sales volume increases.
- Negative P/E ratio of -0.02 reflects current lack of profitability.
- Profit Margin of -76.8% indicates significant losses relative to revenue.
- The company has 5 employees, highlighting its small size and potential operational constraints.
- Beta of -39.80 suggests an inverse correlation with the market, but may be unreliable due to limited trading volume.
Competitors & Peers
Strengths
- Proprietary NIMBUS, Stay Fresh, and MultiStat technologies.
- Potential for diverse applications in healthcare, textiles, and personal care.
- Existing relationships with government agencies.
- High gross margin (69.8%) indicates potential for profitability.
Weaknesses
- Small size and limited resources (5 employees).
- Negative profit margin (-76.8%) indicates significant losses.
- OTC market listing introduces liquidity and regulatory risks.
- Limited brand recognition and market presence.
Catalysts
- Upcoming: Potential FDA approval for new medical applications of NIMBUS technology (Timeline: 1-2 years).
- Ongoing: Expansion of licensing agreements for Stay Fresh formulation in the textile industry.
- Ongoing: Development of strategic partnerships with larger pharmaceutical companies for commercialization.
- Upcoming: Publication of clinical trial results for MultiStat technology in skin therapy (Timeline: 6-12 months).
Risks
- Ongoing: Limited financial resources and negative profitability.
- Potential: Intense competition from larger pharmaceutical and healthcare companies.
- Potential: Stringent regulatory requirements and lengthy approval processes.
- Ongoing: OTC market listing introduces liquidity and regulatory risks.
- Potential: Dependence on key personnel and potential loss of intellectual property.
Growth Opportunities
- Expansion into the Healthcare Market: Quick-Med's NIMBUS technology, with its antimicrobial and hemostatic properties, can be further developed for wound care and surgical applications. The global wound care market is projected to reach $22 billion by 2028, presenting a significant opportunity for Quick-Med to capture market share through strategic partnerships and product innovation. Timeline: 2-3 years for product development and regulatory approvals.
- Penetration of the Textile Industry: The Stay Fresh formulation offers a durable antimicrobial solution for textiles, addressing the growing demand for hygienic and odor-resistant apparel. The global antimicrobial textiles market is estimated at $10 billion, with increasing adoption in sportswear, healthcare garments, and home textiles. Quick-Med can expand its market presence through collaborations with textile manufacturers and brands. Timeline: 1-2 years for partnership development and product integration.
- Development of Advanced Skin Therapy Products: The MultiStat technology can be leveraged to create innovative skin therapy products targeting various dermatological conditions. The global skin therapy market is projected to reach $40 billion by 2027, driven by increasing consumer awareness and demand for effective skincare solutions. Quick-Med can focus on developing niche products with unique formulations and clinical validation. Timeline: 2-3 years for product development and clinical trials.
- Strategic Partnerships with Government Agencies: Quick-Med can pursue collaborations with government agencies to develop and supply antimicrobial solutions for defense and public health applications. Government contracts offer stable revenue streams and opportunities for long-term growth. The company can leverage its NIMBUS technology to address specific needs in areas such as wound care and infection control. Timeline: Ongoing, with continuous engagement and proposal submissions.
- Licensing and Technology Transfer: Quick-Med can generate revenue by licensing its proprietary technologies to other companies in the healthcare, textile, and personal care industries. Licensing agreements provide a low-risk approach to expanding market reach and generating royalty income. The company can focus on identifying potential licensees with complementary capabilities and market access. Timeline: Ongoing, with continuous evaluation of licensing opportunities.
Opportunities
- Expansion into the wound care market with NIMBUS technology.
- Penetration of the antimicrobial textiles market with Stay Fresh formulation.
- Development of advanced skin therapy products with MultiStat technology.
- Strategic partnerships with larger industry players for commercialization.
Threats
- Intense competition from larger pharmaceutical and healthcare companies.
- Stringent regulatory requirements and lengthy approval processes.
- Pricing pressures and reimbursement challenges.
- Potential for technological obsolescence.
Competitive Advantages
- Proprietary Technologies: Patented NIMBUS, Stay Fresh, and MultiStat technologies provide a competitive edge.
- Specialized Expertise: Focus on antimicrobial and hemostatic solutions creates a niche market position.
- Established Relationships: Existing relationships with government agencies and healthcare providers offer a stable customer base.
About QMDT
Founded in 1997 and headquartered in Gainesville, Florida, Quick-Med Technologies, Inc. is a life sciences company dedicated to the research, development, and commercialization of proprietary technologies aimed at the medical and consumer healthcare markets. The company specializes in creating innovative biomedical products and devices with a focus on antibacterial applications. Quick-Med's core technologies include the Novel Intrinsically Micro-Bonded Utility Substrate (NIMBUS), a family of advanced polymers exhibiting antimicrobial and hemostatic properties suitable for various applications. Additionally, they offer Stay Fresh, a chemical formulation designed for textiles, providing durable antimicrobial protection against a broad spectrum of bacteria. Their MultiStat technology represents a collection of patented methods and compounds geared towards advanced skin therapy applications. Quick-Med Technologies serves a diverse clientele, including government agencies, healthcare and medical organizations, apparel and textile manufacturers, and personal care companies, providing them with specialized solutions based on their unique technology platforms. The company's focus on innovation and specialized applications positions it within the niche market of advanced antimicrobial and hemostatic technologies.
What They Do
- Develop proprietary antimicrobial technologies.
- Create hemostatic products for medical applications.
- Formulate antimicrobial solutions for textiles.
- Research and develop skin therapy products.
- Serve government agencies with specialized solutions.
- Cater to healthcare and medical companies.
- Provide solutions for the apparel and textile industry.
- Offer products for the personal care market.
Business Model
- Develop and patent proprietary technologies in the antimicrobial and hemostatic fields.
- Commercialize these technologies through direct sales to government agencies and healthcare providers.
- License technologies to companies in the textile and personal care industries.
- Generate revenue through product sales, licensing fees, and royalty agreements.
Industry Context
Quick-Med Technologies operates within the specialty and generic drug manufacturing industry, characterized by intense competition and stringent regulatory requirements. The market is driven by an increasing demand for advanced antimicrobial and hemostatic solutions across healthcare, textiles, and personal care sectors. Companies like Quick-Med differentiate themselves through proprietary technologies and specialized applications. The industry is subject to evolving regulatory standards and pricing pressures, requiring companies to continuously innovate and adapt to maintain competitiveness. The overall drug manufacturing industry is projected to grow, driven by aging populations and increasing healthcare expenditure.
Key Customers
- Government agencies requiring antimicrobial solutions.
- Healthcare and medical companies seeking advanced wound care products.
- Apparel and textile manufacturers looking for antimicrobial fabrics.
- Personal care companies developing skin therapy products.
Financials
Chart & Info
Quick-Med Technologies, Inc. (QMDT) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for QMDT.
Price Targets
Wall Street price target analysis for QMDT.
MoonshotScore
What does this score mean?
The MoonshotScore rates QMDT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Gregory S. Schultz
CEO
Gregory S. Schultz serves as the CEO of Quick-Med Technologies, Inc. His background includes experience in managing small teams and guiding the strategic direction of the company. He is responsible for overseeing the development and commercialization of the company's proprietary technologies in the medical and consumer healthcare markets. His leadership is crucial for navigating the challenges of a small company operating in a competitive industry.
Track Record: Under Gregory S. Schultz's leadership, Quick-Med Technologies has focused on developing and patenting its core technologies, including NIMBUS, Stay Fresh, and MultiStat. Key milestones include securing government contracts and establishing relationships with healthcare providers. The company has also focused on exploring licensing opportunities to expand its market reach.
QMDT OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Quick-Med Technologies may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial information available and may be subject to greater regulatory scrutiny. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and potential for fraud or manipulation. This tier contrasts sharply with exchanges like NYSE or NASDAQ, which have much stricter listing requirements.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Liquidity: Difficulty in buying or selling shares due to low trading volume.
- Lack of Transparency: Limited financial information and regulatory oversight.
- Price Volatility: Potential for significant price swings due to speculative trading.
- Dilution Risk: Potential for the company to issue new shares, diluting existing shareholders' ownership.
- Going Concern Risk: Uncertainty about the company's ability to continue operating due to financial losses.
- Verify the company's financial statements and SEC filings (if any).
- Research the backgrounds of the company's management team and board members.
- Assess the company's intellectual property and patent portfolio.
- Evaluate the company's competitive landscape and market position.
- Understand the company's business model and revenue streams.
- Determine if the company is subject to any regulatory investigations or legal proceedings.
- Consult with a qualified financial advisor before investing.
- Patented Technologies: Proprietary NIMBUS, Stay Fresh, and MultiStat technologies.
- Government Contracts: Existing relationships with government agencies.
- Scientific Publications: Peer-reviewed publications supporting the efficacy of their technologies.
QMDT Healthcare Stock FAQ
What does Quick-Med Technologies, Inc. do?
Quick-Med Technologies, Inc. is a life sciences company focused on developing and commercializing proprietary technologies in the medical and consumer healthcare markets. It specializes in biomedical products and devices for antibacterial applications. Their core technologies include NIMBUS (antimicrobial polymers), Stay Fresh (antimicrobial textile formulation), and MultiStat (skin therapy compounds). The company serves government agencies, healthcare providers, apparel manufacturers, and personal care companies, aiming to provide innovative solutions in infection control and skin health.
What do analysts say about QMDT stock?
As of March 17, 2026, there is limited analyst coverage available for Quick-Med Technologies, Inc. due to its OTC listing and small market capitalization. Key valuation metrics, such as P/E ratio (-0.02) and profit margin (-76.8%), reflect the company's current lack of profitability. Investors should conduct thorough due diligence and consider the risks associated with investing in OTC stocks before making any investment decisions. The company's growth potential hinges on successful commercialization of its proprietary technologies.
What are the main risks for QMDT?
The main risks for Quick-Med Technologies, Inc. include its limited financial resources, negative profitability, and OTC market listing. The company faces intense competition from larger pharmaceutical and healthcare companies and is subject to stringent regulatory requirements. Liquidity is a significant concern due to low trading volume, and there is a risk of dilution if the company issues new shares. Investors should carefully consider these risks before investing in QMDT.
What are the key factors to evaluate for QMDT?
Quick-Med Technologies, Inc. (QMDT) currently holds an AI score of 57/100, indicating moderate score. Key strength: Proprietary NIMBUS, Stay Fresh, and MultiStat technologies.. Primary risk to monitor: Ongoing: Limited financial resources and negative profitability.. This is not financial advice.
How frequently does QMDT data refresh on this page?
QMDT prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven QMDT's recent stock price performance?
Recent price movement in Quick-Med Technologies, Inc. (QMDT) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary NIMBUS, Stay Fresh, and MultiStat technologies.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider QMDT overvalued or undervalued right now?
Determining whether Quick-Med Technologies, Inc. (QMDT) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying QMDT?
Before investing in Quick-Med Technologies, Inc. (QMDT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available for OTC-listed companies.
- Financial data based on available public information.